Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...

Olaparib monotherapy may be a treatment option for some patients with high-risk biochemically recurrent prostate cancer, according to researchers.

New Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...

The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Some 800 people in total will be eligible for the treatment. Around 500 men with advanced ...

This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients ...

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the ...

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...

AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the CDSCO, ...

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...

Get detailed information on Olaparib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Around 500 men with advanced prostate cancer and 300 women with HER2-negative early ...